Table 2.

Univariate survival analysis of OS and DFS in 596 patients after mastectomy

Variable	N	OS(%)		P value	DFS(%)		P value
		5-y	8-y		5-y	8-y
Age, y				0.007			0.007
≤ 40	44	84.0	73.8		72.6	67.5
>40	552	93.3	91.6		88.9	83.6
Tumor location				0.003			0.021
Outer	402	93.5	90.2		88.5	84.7
Inner/central	194	90.7	82.2		86.0	77.5
Histological grade				0.418			0.630
I	13	100	100		100	100
II	300	93.0	87.7		89.3	83.1
III	164	90.2	86.3		81.7	79.5
Unknown	119	94.1	88.0		90.7	82.7
ER/PR status				0.167			0.806
Positive	483	93.4	88.7		88.8	82.8
Negative	113	89.3	83.4		83.1	80.9
HER-2 status				0.439			0.329
Negative	373	94.1	88.5		89.2	83.4
Positive	151	89.3	87.2		86.7	84.3
Unknown	72	91.7	84.7		81.9	73.7
Ki-67,%				0.011			0.172
≤ 30	312	95.5	90.9		91.3	84.4
>30	284	89.4	84.3		83.8	81.8
NRN				0.241			0.258
<10	14	78.6	78.6		78.6	70.7
≥ 10	582	92.9	87.9		87.9	82.7
LNM				0.029			0.089
1	351	95.1	90.8		89.7	84.8
2	182	90.0	83.5		85.6	78.4
3	63	85.7	82.1		82.5	80.7
Stagea				0.004			0.005
T1	275	95.6	91.0		92.7	86.4
T2	321	90.0	84.8		83.4	79.0
LVI				0.054			0.417
No	381	93.9	89.9		89.5	83.5
Yes	215	90.2	83.9		84.7	80.5

Abbreviations LVI: lymphovascular invasion; NRN: number of removed nodes; LNM: lymph node metastasis; ER/PR: Estrogen Receptor/Progesterone Receptor; HER-2: Human epidermal growth factor receptor 2; OS: Overall survival; DFS: Disease-free survival

^aOnly including T stage